PREXATE 20 mg/ 0.50 ml, solution for injection in a pre-filled syringe syringe, 0.5 ml
Active ingredients: Methotrexate
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PREXATE 20 mg/ 0,50 ml, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 0,5 ml avec 1 tampon alcoolisé
- Marketing authorisation holder
- ALFASIGMA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 21 Dec 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68645071CIP73012088CIP133400930120880Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MÉTHOTREXATEsolution | 20 mg · 1 seringue préremplie de 0,50 ml | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.